Time course and recovery of arterial blood gases during exacerbations in adults with Cystic Fibrosis

Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
D F WaterhouseC G Gallagher

Abstract

Hypoxia and hypercapnia are closely linked to morbidity and mortality in patients with Cystic Fibrosis (CF). The aims of this study were to describe the changes in blood gases during and following an acute pulmonary exacerbation in adults with CF. We performed a prospective observational study of patients with CF admitted for management of an acute exacerbation. Blood gas and spirometric analysis was performed on admission, throughout the treatment period, and 31 days after discharge (day 45). At presentation, eight of nineteen patients had evidence of either hypoxia (PaO(2)<8 kPa) and/or hypercapnia (PaCO(2)>6.6 kPa). Blood gas parameters stabilized following two weeks of intravenous antibiotic therapy, with little difference evident in between treatment completion and subsequent review following discharge. Hypercapnia reversed in three patients, with persistent hypercapnia evident in two patients. In our study group, hypoxemia and hypercapnia were frequently observed at presentation of the acute exacerbation. Blood gases stabilized following two weeks of intravenous antibiotic therapy, with arterial PCO(2) one month following hospital discharge generally similar to that at time of discharge.

References

Jan 1, 1978·Acta paediatrica Scandinavica·R KraemerE Rossi
Apr 30, 1992·The New England Journal of Medicine·E KeremH Levison
Sep 1, 1995·American Journal of Respiratory and Critical Care Medicine
Jan 1, 1993·The Journal of Pediatrics·S C FitzSimmons
Mar 18, 1999·Baillière's Clinical Gastroenterology·D Turck, L Michaud
Dec 26, 2001·JAMA : the Journal of the American Medical Association·T G LiouB C Marshall
Oct 31, 2002·American Journal of Respiratory and Critical Care Medicine·Nicole Mayer-HamblettMoira L Aitken
Dec 13, 2003·American Journal of Respiratory and Critical Care Medicine·Shawn D AaronFrancis Chan
Jan 22, 2004·Chest·James R YankaskasDavid Rodman
Oct 27, 2004·American Journal of Respiratory and Critical Care Medicine·Madiha EllaffiDaniel Dusser
Jul 26, 2005·Archives of Disease in Childhood·S M JavadpourA L Coates
Aug 10, 2005·Seminars in Respiratory and Critical Care Medicine·Michael Eckles, Paula Anderson

❮ Previous
Next ❯

Citations

Oct 14, 2009·Pediatric Pulmonology·Claudia de Castro-SilvaPedro Felipe Carvalhedo de Bruin
Sep 3, 2021·Pneumologie·Jens GottliebThomas Fühner
Nov 10, 2021·Pediatric Pulmonology·Aesha JobanputraSreelatha Naik

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CFTR Mutant Structural Therapy

Over 1700 different mutations in the CFTR genes have been shown to cause cystic fibrosis. Here is the latest research on structural therapy for CFTR mutants.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.